AKCEA THERAPEUTICS INC's ticker is AKCA and the CUSIP is 00972L107. A total of 45 filers reported holding AKCEA THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $24,904,000 | +24.2% | 1,372,903 | -6.2% | 0.00% | 0.0% |
| Q2 2020 | $20,058,000 | +0.8% | 1,464,135 | +5.2% | 0.00% | 0.0% |
| Q1 2020 | $19,907,000 | -13.2% | 1,392,082 | +2.8% | 0.00% | 0.0% |
| Q4 2019 | $22,941,000 | -12.4% | 1,354,282 | -20.4% | 0.00% | 0.0% |
| Q3 2019 | $26,193,000 | -30.3% | 1,701,960 | +6.2% | 0.00% | 0.0% |
| Q2 2019 | $37,565,000 | +2.7% | 1,601,976 | +24.1% | 0.00% | 0.0% |
| Q1 2019 | $36,563,000 | -2.4% | 1,290,610 | +3.8% | 0.00% | -50.0% |
| Q4 2018 | $37,466,000 | -10.2% | 1,243,073 | +4.3% | 0.00% | 0.0% |
| Q3 2018 | $41,727,000 | +51.7% | 1,191,511 | +2.7% | 0.00% | +100.0% |
| Q2 2018 | $27,499,000 | -4.4% | 1,159,797 | +3.2% | 0.00% | 0.0% |
| Q1 2018 | $28,779,000 | +40.5% | 1,123,758 | -4.8% | 0.00% | 0.0% |
| Q4 2017 | $20,487,000 | -31.1% | 1,180,095 | +9.8% | 0.00% | 0.0% |
| Q3 2017 | $29,744,000 | – | 1,074,960 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iguana Healthcare Management, LLC | 100,000 | $1,736,000 | 1.13% |
| BB BIOTECH AG | 1,248,650 | $21,677,000 | 0.61% |
| Virtus ETF Advisers LLC | 18,071 | $314,000 | 0.39% |
| Eventide Asset Management | 420,000 | $7,291,000 | 0.38% |
| Granahan Investment Management | 194,376 | $3,374,000 | 0.26% |
| ALTRINSIC GLOBAL ADVISORS LLC | 150,000 | $2,604,000 | 0.10% |
| Candriam S.C.A. | 114,571 | $1,990,000 | 0.03% |
| ARDSLEY ADVISORY PARTNERS LP | 15,000 | $260,000 | 0.03% |
| Delpha Capital Management, LLC | 1,521 | $26,000 | 0.03% |
| FMR LLC | 9,981,244 | $173,274,000 | 0.02% |